The pathological constriction of cerebral arteries known as cerebral vasospasm (CVS) is with a delay of 4 to 10 days linked to subarachnoid hemorrhage. Several agents have been suggested as being responsible; amongst these perhaps 5-hydroxytryptamine (5-HT) and endothelin-1 (ET-1) are the most prominent given their ability to elicit powerful constriction of cerebral arteries. Investigating both 5-HT and ET receptors we have observed that there are distinct changes in receptor phenotype after experimental SAH, namely upregulation of the ET B and 5-HT 1B receptors, and that this upregulation is linked to a higher sensitivity to the endogenous agonists. It has also been shown that reduction in regional cerebral blood flow (CBF) is associated with receptor upregulation and interventional animal experiments have shown a benefit from inhibiting the PKC and MAP kinase pathways on receptor upregulation, CBF and neurological outcome.
ABSTRACT
The pathological constriction of cerebral arteries known as cerebral vasospasm (CVS) is with a delay of 4 to 10 days linked to subarachnoid hemorrhage. Several agents have been suggested as being responsible; amongst these perhaps 5-hydroxytryptamine (5-HT) and endothelin-1 (ET-1) are the most prominent given their ability to elicit powerful constriction of cerebral arteries. Investigating both 5-HT and ET receptors we have observed that there are distinct changes in receptor phenotype after experimental SAH, namely upregulation of the ET B and 5-HT 1B receptors, and that this upregulation is linked to a higher sensitivity to the endogenous agonists. It has also been shown that reduction in regional cerebral blood flow (CBF) is associated with receptor upregulation and interventional animal experiments have shown a benefit from inhibiting the PKC and MAP kinase pathways on receptor upregulation, CBF and neurological outcome.
ASPECTS OF RECEPTOR UPREGULATION IN CEREBRAL ARTERIES

Changes in the vascular receptor phenotype
Some years ago it was discovered that segments of the rat and human arteries were able to change their receptor phenotype in the process of organ culture (1;2). Specifically the appearance of a contractile ETB receptor phenotype was noted (2) . This was in stark contrast to the situation in normal fresh arteries where stimulation of the ETB receptor only produced a relaxant response (1) . This discovery provided the impetus for the in-depth investigation of organ culture induced changes in the receptor phenotype of cerebral arteries and, given the focus on arterial narrowing as paramount in cerebral vasospasm, also for testing whether such alterations could play a role in this syndrome (3;4) . Concentration-contraction curves (human cerebral artery) showing the inhibitory effect of Actinomysin D (AcD) and Cyclohexamide (CHX) on the enhanced ET-1 response after organ culture. Clearly AcD inhibits the enhancement, the curve being similar to the fresh. CHX has a partial inhibiting effect; this was concluded not to be lack of effect, rather higher concentrations could not be employed for reasons of toxicity. The results indicate that gene expression is necessary to achieve the altered pharmacological phenotype.
ET receptor upregulation in cerebral arteries
The rat basilar artery was shown to exhibit a markedly altered receptor phenotype after organ culture (3). In fresh basilar artery ET-1 produced an ET A receptor dependent contraction with an E max of 122±15% and pEC 50 8.7±0.1. The specific ET B receptor agonist S6c did not produce contraction in the fresh artery, but upon precontraction with U46619 a powerful endothelium dependent dilatation was observed. These observations were fully in line with those done on peripheral arteries in the rat (2) as well as on cerebral arteries from other species (5).
In situations of organ culture, the pattern of reactivity was modified dramatically; after 48 hours of organ culture the sensitivity to ET-1 had increased 1000-fold, pEC 50 now being 11.7±0.3, but without change in E max compared to fresh arteries. Also, S6c now gave rise to a powerful ET B receptor dependent contraction with an E max of 98±3% and pEC 50 of 10.6±0.3 ( Figure 1 ).
Fresh human cortical arteries (removed in conjunction with neurosurgery) have been investigated by Nilsson et al. (6) . They observed an ET A receptor mediated contraction in response to ET-1 with an E max of 112±8% and a pEC 50 of 9.2±0.2. In response to S6c an ET B receptor mediated dilatation was observed, though the effect was not as pronounced as the one observed in rat cerebral arteries. In cultured human cerebral arteries the picture was somewhat different compared to the observations done on rat basilar arteries (7) . In similarity, the response to ET-1 increased both in terms of sensitivity and potency, E max 152±9% and pEC 50 10.3±0.2 ( Figure  2 ). The contraction was solely (in the pharmacological sense) ET A receptor dependent.
However, and in contrast, S6c did not elicit any contraction.
In arteries from rats with induced SAH, an increased response to ET-1 was observed (8) . In similarity with the results obtained with cultured human cerebral arteries, no contractile response toward S6c was observed, and the ET-1 induced contraction was shown to be dependent on the ET A receptor. The data were supplemented by quantitative RT-PCR, which showed the remarkable result that there was no increase in the number of ET A receptor mRNA copies; on the contrary, the number of ET B receptor copies was 4-fold increased.
It therefore seems reasonable to conclude that the appearance of the ET B receptor is instrumental in the process of increased pharmacological sensitivity to ET-1, although this receptor need not be functional in the sense of being able to produce contraction upon selective stimulation. The importance of the ET B receptor was furthermore confirmed in the SAH experiments since the ET-1 induced contraction in segments of cerebral arteries could be attenuated through either pre-treatment with the specific ET B receptor antagonist IRL 1038 or through desensitising any present ET B receptors by with S6c (used as pretreatment). In the posterior communicating artery, no significant changes were observed (not shown). Molecular analysis ( Figure 5 ) showed increased transcription of the ET B receptor. Selective ET B stimulation did not give rise to a functional response; thus, a complex interaction between the two ET receptors must be responsible for the enhanced response. At present the nature of interaction between the ET A and the ET B receptors may only be speculated at. It could range from possible dimerisation in the cell membrane over receptor synergism to interaction between the signal transduction pathways of the two receptors. In the ET-1 elicited contraction in small mesenteric arteries, Mickley et al. (9) found that ET B receptors contributed more to the contraction than could be predicted through the response to S6c alone, thus, also making allusion to collaboration between the two receptors. They termed this collaboration "cross-talk".
The role of the ET B receptor in arterial narrowing of the cerebral arteries after experimental SAH has also been studied by Vatter et al. (10; 11; 12) . In agreement with the aforementioned observations they did not find any contractile of effect of selective ET B receptor stimulation, but did observe a time dependent decline in the dilatatory effect of ET B receptor stimulation. In contrast, however, quantitative protein analysis did not reveal any increase in ET B receptor protein in SMC.
5-HT receptor upregulation in cerebral arteries
In fresh rat basilar artery 5-HT elicits a concentration-dependent contraction with an E max of 82±6% and a pEC 50 of 7.2±0.1, comparable to previously reported values (13) . The contraction was found dependent on the 5-HT 2A receptor. 5-CT, a fairly specific agonist for the 5-HT 1 receptor group, produced a biphasic response with an initial phase of low efficacy and a second with appreciable contraction. The first phase, but not the second, could be attenuated using the specific antagonist GR 55562 (specific 5-HT 1B/1D antagonist) indicating the vestigial presence of a 5-HT 1B/1D receptor in fresh arteries, and indicating a degenerate 5-HT 2A receptor response at high concentrations.
In cultured arteries, 5-CT gave rise to a powerful contraction with an E max of 113±11% and a pEC 50 of 6.8±0.4; a contraction that was competitively inhibited by GR 55562, thus indicating upregulation of a 5-HT 1B/1D type receptor. The response to 5-HT in cultured arteries was also increased compared to fresh arteries, E max being 117±4% and pEC 50 7.3±0.4 ( Figure  1) .
The functional results were confirmed using ordinary RT-PCR identifying 5-HT 1B , 5-HT 1D , and 5-HT 2A receptor mRNA.
In the MCA and basilar artery from rats with induced SAH, the 5-HT 1B receptor was also found upregulated, both functionally and in terms of number of mRNA copies (Figures 4 and 5)(14) . Thus, 5-CT yielded an increased response in comparison to arteries from sham-operated animals, and the response could be attenuated using GR 55562. For the SAH studies quantitative RT-PCR was used. 5-HT 1D receptor mRNA was only found in negligible amounts. In contrast, the number of mRNA copies for the 5-HT 1B receptor was increased 5-fold ( Figure 5 ). In conclusion, among the 5-HT receptors it appears to be the 5-HT 1B/1D receptor that is plastic, i.e. capable of being upregulated. 
The signal transduction pathway mediating receptor upregulation
It has been shown that the upregulation of receptors is an active process; co-culture with Actinomycin D inhibiting transcription prevented the phenotypical receptor changes described above (Figure 2 ) (10). Based on results gathered using in vitro organ culture of arterial segments where PKC and MAP kinases were found to be involved in the signal transduction process (15;16), a series of interventional experiments in a rat SAH model was conducted. PKC and MAPK inhibitors were administered in conjunction with the SAH as well as immediately after, observing whether this treatment blocked changes in receptor mRNA, receptor protein and vascular function, and most importantly, whether the SAH induced reduction in global and regional CBF and neurological score was prevented.
Experimental SAH in the rat gave rise to a significant drop in global CBF from 131±7 ml/l00g/min (as measured in the control group) to 60±4 ml/l00g/min after 48 hours of observation. Intrathecal administration of the PKC inhibitor RO-31-7549 (blocker of the classical and novel PKC's) did to some extent prevent the reduction in global CBF reaching a level of 115±6 ml/l00g/min ( Figure  6 )(4). As for regional CBF similar results were observed in 14 out of the 18 brain regions studied (Table 1 in (4)). Furthermore, the SAH induced enhancement of contractile responses to ET-1 and 5-CT in cerebral arteries was inhibited. As for protein levels, immunohistochemistry using specific receptor antibodies showed lower levels of vascular ET B and 5-HT 1B receptor protein in rats treated with RO-31-7549. In parallel, the increase in mRNA for these receptors was also prevented. For the study of the MAP kinase pathway the inhibitor SB386023-b was chosen (16) .
SB386023-b inhibits MAPKKK upstream of ERK1/2. Intrathecal treatment with SB386023-b efficiently prevented the aforementioned reduction in CBF after SAH to a level of 125±7 ml/l00g/min ( Figure 7 ) (17) . Furthermore, as observed before, the SAH induced enhancement of the contractile responses to ET-l and 5-CT in cerebral arteries was prevented. In addition, administration of SB386023-b prevented the upregulation of ET B and 5-HT 1B receptor mRNA and protein levels otherwise observed after SAH.
MAJOR CONCLUSIONS
• Cerebral arteries have an inherent capacity to increase their sensitivity to endogenous agonists such as ET-1 and 5-HT. It may be induced through organ culture of discrete arterial segments, but may also be induced in vivo in a rat model of SAH. Receptor upregulation and reduction in CBF (both globally and regionally) after experimental SAH have been associated.
• In the ET and 5-HT receptor systems, it is the ET B and 5-HT 1B receptors that are inducible. In terms of increased sensitivity to 5-HT, it seems governed by the appearance of the 5-HT 1B receptor, whereas the increased sensitivity to ET-1 involves the ET B receptor, but probably also involving a complex interplay between the ET A and the ET B receptors.
• The upregulation of receptors is an active process involving gene transcription and gene translation. Also, signal transduction pathways are involved. Both the PKC and MAP kinase pathways have been shown to be involved both in vitro and experimental SAH. In the latter case inhibition of these pathways leads to normalization of CBF and prevents receptor upregulation.
